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Accurate quantiﬁcation of apoptosis progression
and toxicity using a dielectrophoretic approach†
Erin A. Henslee,a Ruth M. Torcal Serrano,a Fatima H. Labeed,a Rita I. Jabr,b
Christopher H. Fry,‡b Michael P. Hughes*a and Kai F. Hoettges§a
A loss of ability of cells to undergo apoptosis (programmed cell death, whereby the cell ceases to func-
tion and destroys itself ) is commonly associated with cancer, and many anti-cancer interventions aim to
restart the process. Consequently, the accurate quantiﬁcation of apoptosis is essential in understanding
the function and performance of new anti-cancer drugs. Dielectrophoresis has previously been demon-
strated to detect apoptosis more rapidly than other methods, and is low-cost, label-free and rapid, but
has previously been unable to accurately quantify cells through the apoptotic process because cells in
late apoptosis disintegrate, making cell tracking impossible. In this paper we use a novel method based on
light absorbance and multi-population tracking to quantify the progress of apoptosis, benchmarking
against conventional assays including MTT, trypan blue and Annexin-V. Analyses are performed on
suspension and adherent cells, and using two apoptosis-inducing agents. IC50 measurements compared
favourably to MTT and were superior to trypan blue, whilst also detecting apoptotic progression faster
than Annexin-V.
Introduction
The study of apoptosis, or programmed cell death, is of great
significance because it plays an important role in the normal
development of multi-cellular organisms. Problems with the
regulation of apoptosis can lead to diseases such as cancer
(too little apoptosis) or neurodegenerative conditions such as
Parkinson’s or Alzheimer’s diseases (too much apoptosis).
New compounds that regulate apoptotic pathways can have
applications as therapeutic agents, and hence quantifying the
eﬀectiveness of the new compounds is essential in drug dis-
covery. Apoptotic cell death has a distinct cytological
morphology and the signalling cascade is regulated at several
points, therefore, there are many methods and opportunities
to evaluate apoptotic death. There are several assays for apop-
tosis detection and understanding the mode of operations,
their pros and cons, as well as the limitations of each assay is
important. The process of apoptotic cell death can be com-
pleted in a few hours, and therefore if the assay is performed
too early or too late, the results may not be accurate. Of the
methods used to study apoptosis, spectroscopic techniques are
standard, though new options are emerging.1 Most spectro-
scopic techniques for apoptosis rely on fluorescence detection
of immunochemical labels or fluorescent probes which react
to the cell environment during apoptosis. There are several
options available including Annexin V staining, the TUNEL
assay, and measurement of mitochondrial membrane poten-
tial.1 These assays measure diﬀerent parameters which corre-
late with apoptotic progression. Trypan blue inclusion in cells
measures surface membrane integrity by assessing the
number of cells that will allow trypan blue to enter the cell
interior. The MTT assay is a colourimetric assay to assess cell
metabolic activity, as viable cells with an active metabolism
convert MTT into a purple coloured formazan product. The
TUNEL assay detects DNA fragmentation by labelling the term-
inal end of nucleic acids and such DNA fragmentation is a
characteristic hallmark of apoptosis. The Annexin-V assay
measures the loss of phospholipid asymmetry in the cell mem-
brane which occurs early in the apoptotic process; phosphati-
dylserine, which is usually in the inner membrane leaflet, is
transported to the outer leaflet as an “eat me” signal to macro-
phages;2 fluorescence labelling of Annexin V, combined with a
nuclear stain, allows distinguishing between healthy, early
apoptotic and late apoptotic cells using flow cytometry.3 The
early apoptotic phase can be quite brief, and so experiments at
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c6an01596d
‡Present address: School of Physiology and Pharmacology, University of Bristol,
University Walk, Bristol BS8 1TD, UK.
§Present address: Department of Electrical Engineering and Electronics,
University of Liverpool, Brownlow Hill, Liverpool L69 3GJ, UK.
aCentre for Biomedical Engineering, Department of Mechanical Engineering Sciences,
University of Surrey, Guildford, Surrey GU2 7XH, UK. E-mail: m.hughes@surrey.ac.uk
bFaculty of Health and Medical Sciences, University of Surrey, Guildford,
Surrey GU2 7XH, UK
6408 | Analyst, 2016, 141, 6408–6415 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
O
ct
ob
er
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
1/
11
/2
01
6 
15
:2
6:
52
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal  | View Issue
diﬀerent drug incubation times must be performed to
prove that cells exhibit early apoptosis before reaching late apop-
tosis/necrosis. Whilst Annexin is fairly robust when used in sus-
pensions growing cells, the use of flow cytometry can produce
anomalous results due to damage caused by shear forces.4
In addition to indicating the presence or absence of apopto-
sis in the cell population, new compounds need to be quanti-
fied in their eﬀectiveness or cytotoxicity. In most cases this is
measured using the half maximal inhibitory concentration
(IC50), which indicates the necessary drug concentration to
inhibit a biological process on a cell population by half. There
are various types of tests that are typically used to determine
the IC50 of a drug including simple light microscopy such as
viability measures with trypan blue, fluorescent microscopy,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT) assay,5 and characterising cell populations through flow
cytometry.6 All of these methods involve staining of the cells
often with expensive and cytotoxic dyes, lengthy preparation
procedures, and rely on cellular events that occur as a result of
drug exposure downstream of the initial drug eﬀect. There is
also the added complexity of comparing methods, as each
measures viability mechanistically.
Dielectrophoresis (DEP) has been used as an alternative
method of analysing the onset of apoptosis in the past, having
been used to detect changes in cell phenotype within
30 minutes of drug incubation.7 DEP was first demonstrated to
be capable of detection physiological changes in apoptosis in
2002,8 when Wang et al. demonstrated that the technique
could more sensitively detect apoptotic induction than
common methods such as the Annexin-V assay, using cross-
over methods to study changes in the cell membrane.
Subsequent work compared DEP and Annexin-V for both mem-
brane and cytoplasm, and found that DEP could detect apopto-
sis considerably earlier than the conventional test for PS
expression in K562 cells, and that early events in apoptosis
such as the calcium activated translocation of the negatively
charged phospholipid phosphatidylserine (PS) and the
reduction of intracellular potassium all precede membrane
degradation and thus detection by methods such as trypan
blue or MTT.8–14 More recent work has used the detection of
apoptosis as a test for new DEP-based cytometry and cell
sorting devices;15–20 in all cases, devices were presented that
were able to sort apoptotic from non-apoptotic cells, indicating
again that apoptosis can be measured according to changes in
cell electrophysiology.
Whilst DEP has been conclusively shown to be able to dis-
criminate between apoptotic and non-apoptotic cells, analyses
have thus far been based on the analysis of intact cells in the
early stages of apoptosis. In fact, a key stage in the apoptotic
progress is the disintegration of the cell into apoptotic bodies,
which cannot be detected by most DEP methods, preventing
DEP from accurately quantifying apoptosis progression across a
population. This is significant, because whilst DEP can be used
to identify whether a given cell is apoptotic or not, it is signifi-
cantly more diﬃcult to quantify apoptosis across a population
in order to assess, for example, the concentration of a drug
required to induce apoptosis (the IC50); such a measurement
would require the detection and quantification of apoptotic
bodies (typically 1 µm across) as well as intact cells.
In this paper, we use a DEP analysis technique which ana-
lyses light absorbance changes due to DEP, hence allowing the
quantification of apoptotic bodies. The DEP method was
benchmarked with a suspension cell line (Jurkat) and the
widely-used anti-cancer drug doxorubicin (DOX). Then, two
studies were carried out on HeLa (adherent) and Jurkat (sus-
pension) cells to benchmark DEP’s speed and accuracy against
MTT, trypan blue and flow cytometry with Annexin V/PI for
apoptosis. The work demonstrates that with appropriate prepa-
ration, DEP analysis is as accurate as existing techniques
whilst also being faster, simpler and cheaper to perform.
Experimental methods
Cell culture
Jurkat cells were cultivated in modified RPMI-1640 medium
(Biosera, UK) supplemented with 10% heat-inactivated foetal
bovine serum (Invitrogen, UK), 2 mM L-glutamine and 1%
penicillin–streptomycin (Sigma-Aldrich, UK) and sub-cultured
every 48 h.
HeLa cells were cultivated in MEM with Earle’s salts and
non-essential amino acids (Biosera, UK) supplemented with
10% heat-inactivated foetal bovine serum (Invitrogen, UK),
2 mM L-glutamine and 1% penicillin–streptomycin (Sigma-
Aldrich, UK). The medium was changed every 48 h and the
cells were passaged using Accutase® (Sigma-Aldrich, UK) at
around 70% confluence. HeLa cells were seeded at 6000 cells
per cm2 in T175 flasks.
Drug treatments and preparation
Preparing mixtures. Jurkat cells were incubated with a high
dose (10 µM) of doxorubicin hydrochloride (DOX, Sigma-
Aldrich, UK) for 16 h. This incubation was optimized to provide
a control sample where 100% of cells had been aﬀected by DOX.
To prepare cells for the DEP assay, samples were centri-
fuged at room temperature at 259g for 6 minutes and washed
in iso-osmotic DEP medium consisting of 8.5% (w/v) sucrose,
0.5% (w/v) dextrose, 100 µM CaCl2 and 250 µM MgCl2
21
adjusted to a conductivity of 0.01 Sm−1 using phosphate-
buﬀered saline (PBS), and resuspended at a final cell concen-
tration of 106 cells per ml (±15%). To calibrate how well DEP
detects diﬀerent sub-populations in a homogenous sample, a
sample of healthy cells (not treated with DOX) and a sample of
DOX-treated cells were prepared for DEP experiments. Then
ratios of the healthy and the treated cell samples were pre-
pared in ratios of 1 : 3, 2 : 2 and 3 : 1. A viability test was carried
out on 20 μL of each of the mixtures as well as on the original
samples using trypan blue 0.4% solution.
Cytotoxicity measurement. Staurosporine solution (1 mM in
DMSO) from Streptomyces sp. (Sigma-Aldrich, UK) was used to
induce apoptosis. A treatment of 1 µM staurosporine (Sigma-
Aldrich, UK) was added to the HeLa flasks 24 h after seeding,
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in order to ensure exponential growth. Cells were incubated
for 0.5 h, 2 h and 4 h. Before DEP experiments, the drug treat-
ment was terminated by centrifuging, removing the super-
natant and resuspending in DEP media. Healthy HeLa cells
attach to the flask, whereas dying cells lose their ability to
attach and float in the culture medium. After treatment with
staurosporine, supernatants containing detached apoptotic
cells were transferred to new tubes. The remaining cells were
detached following incubation with Accutase® which has been
shown to not significantly alter the DEP properties of the
cells.22 These cells were then centrifuged at room temperature
at 259g for 6 minutes. The supernatant was removed and the
pellets were resuspended in the previously-described experi-
mental medium. The final cell population was adjusted for
DEP measurements to 1.15 × 106 cells per ml (±15%).
IC50 measurement. Doxorubicin (Sigma-Aldrich, UK) was
dissolved in sterile filtered distilled water, to achieve a
1.72 mM stock solution, aliquoted, and kept at 4 °C. Jurkat
cells were treated with 0.1, 0.3, 0.5 or 1 µM doxorubicin (DOX)
24 h after the previous passage to ensure exponential growth.
Cells were incubated with diﬀerent doses of DOX for 8, 16 or
32 h before the drug treatment was terminated. Each of these
samples was centrifuged at room temperature at 259g for
6 minutes in experimental medium, resuspended to a final
cell concentration of 106 cells per ml (±15%).
DEP assay
The DEP assays were conducted on a DEPtech 3DEP well-based
DEP cytometer23–25 (Uckfield, UK). The instrument (Shown in
Fig. 1) uses twenty parallel 3D electrode arrays to infer the DEP
behaviour of a cell population by analysing the radial motion of
cells within the well over a period of 10 seconds. It can measure
the DEP response reliably up to 45 MHz, providing more accurate
information about the dielectric properties of the cytoplasm.
Approximately 80 μL of prepared cell suspension was pipetted
into a 3DEP disposable chip, inserted into the reader and ener-
gized at 10 kHz–20 MHz to produce a full DEP spectrum. This
was repeated for each treatment group at least 5 times. Data
were analysed over 10 s (Jurkat) or 40 s (HeLa) intervals.
A single shelled model26,27 was fitted to the average of the
sample data using the averages of measured cell radii.
The eﬀective permittivity and conductivity of the particle
considering a single shell model is given by:
εp ¼ εm
γ3 þ 2 εc  εm
εc þ 2εm
 
γ3  εc  εm
εc þ 2εm
  ð1Þ
σp ¼ σm
γ3 þ 2 σc  σm
σc þ 2σm
 
γ3  σc  σm
σc þ 2σm
  ð2Þ
where γ = R/(R − d ); R is the particle radius; d is the cell mem-
brane thickness; εc, σc and εm, σm are the complex permittiv-
ities and conductivities of the cytoplasm and the membrane,
respectively.
Broche et al. developed a mathematical method to model
multiple sub-populations within a sample.28 This is achieved
by adding together the individual single-shell models of each
subpopulation at each frequency point. MATLAB (The
MathWorks, Inc., Natick, MA) was used to establish Pearson
correlation coeﬃcients (R) and RMS errors of the final multi-
population fits. All data presented here have R-values >0.99.
Cell radii were obtained by image analysis of cells on a haemo-
cytometer using Image-J (National Institute of Health,
Maryland, US). One hundred cells were measured for each
sample. The distribution of cell size was analysed using SPSS
(SPSS Inc. Chicago, IL).
Flow cytometry measurements
Annexin V FITC Apoptosis detection kit (Sigma-Aldrich, UK) was
used to detect apoptosis using flow cytometry. HeLa cell concen-
tration was adjusted to 106 cells per ml. Staurosporine treat-
ment was applied to the wells at: 0.5 h, 2 h, and 4 h. A control
of non-induced HeLa cells for a zero time point was also estab-
lished. After the drug treatment was terminated, the cells were
brought into suspension and washed twice with PBS. Control
cells were also seeded in order to use them for compensation
adjustments, made to minimise overlap between the two fluoro-
chromes. The cells were resuspended in 1× binding buﬀer at a
concentration of approximately 1 × 106 cells per ml. Annexin
V-FITC (5 µL) and Propidium Iodide (PI: 10 µL) solution were
added to 500 µL of cell suspension. The cells were incubated for
10 min at room temperature and protected from light. After
incubation the cells were analysed using a Beckman Coulter BD
FACSCanto II flow cytometer emitting an excitation light at
488 nm from a laser. The detection was made at 518 nm for
FITC detection and 620 nm for PI detection.
MTT experiments
3-(4,5-Dimethylthiazol-2-yl)-2,5 diphenyltetrazoliumbromide
(MTT) assay experiments were conducted following a protocol
described by Mosmann.5 MTT was used to titrate cell viability
following drug treatment. HeLa cells were treated as described
Fig. 1 Two DEPtech 3DEP cell analysers; the device on the left of the
image is closed (as when in use), the device on the right is open to show
the chip (red) and optical path.
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for flow cytometry, whilst for Jurkat cells, doxorubicin was
added to complete RPMI1640 to achieve final concentrations
of 0.1, 0.3, 0.5 and 1 µM. The cells were seeded at a density of
3.6 × 104 cells per ml, 24 h after the previous passage to ensure
exponential growth, and kept in T25 flasks in 5 ml of medium
with the corresponding concentrations of doxorubicin.
Following incubation for 8, 16, 32 and 48 h, the cells were cen-
trifuged, the supernatant removed, and resuspended in 60 µl
of MTT: 10 µL was plated per well in 6 wells (6 repeats) and
incubated for 4 hours. Following incubation, tetrazolium
crystals were dissolved in 100 µl of DMSO. The absorbance
intensity was measured by a microplate reader (VERSAmax) at
570 nm with a reference wavelength of 690 nm. Plates were
read within 30 minutes of adding the DMSO. All experiments
were performed in quadruplicate and the relative cell viability
(%) was expressed as a percentage relative to the untreated
control cells.
Trypan blue experiments
20 µl of cell suspension was mixed with 20 µl of trypan blue
0.4% solution (Sigma-Aldrich, UK) in order to assess cell viabi-
lity. The test was performed on a haemocytometer. The
number of viable and non-viable cells in the haemocytometer
were counted, and the viability percentage was calculated.
IC50 determination
In pharmacological research, the half maximal inhibitory con-
centration, IC50, is a common toxicity measure which indicates
the concentration of a drug that is needed to inhibit a given
biological process in half of the cells in a population. For
chemotherapeutic agents that are cytotoxic, the IC50 represents
the concentration of the chemotherapeutic agent that is
needed to inhibit population cell growth by half. The cyto-
toxicity of a compound is the extent to which that compound
can damage the cell and this damage is dose dependent.
Cytotoxic compounds can cause cell death in diﬀerent ways
including necrosis and apoptosis. The cytotoxicity can be
determined by incubating cells with a range of concentrations
of a drug for a period of time and quantifying the growth inhi-
bition on the cells by comparing the viability of treated and
healthy control. A dose response graph is typically used in
which the eﬀect of cell growth is plotted as a function of drug
concentration. The Hill equation29 has been widely used to
describe the dose response relationship, in the ‘sigmoid
Emax model’, given by:
E ¼ EmaxC
α
EC50α þ Cα ð3Þ
where E is the predicted eﬀect of the drug, Emax is the
maximum eﬀect, C is the drug concentration, EC50 is the drug
concentration for which 50% of the maximum eﬀect is
obtained and α is the Hill coeﬃcient of sigmoidicity.30 For an
inhibitory eﬀect, values of α are negative.
Results and discussion
Validation of DEP multiple subpopulation model against
known mixtures of healthy and treated cells
It has previously been shown that when DEP analysis is per-
formed on heterogeneous cell populations, the resulting DEP
spectrum is the mathematical point-wise addition of the
spectra of separate sub-populations.24,28 Consequently, if the
data are of suﬃcient quality, it is possible to model multiple
populations by identifying separate dispersions and other
characteristic features in the recorded spectrum. The accuracy
of this is increased further where the populations can be
characterised in advance.
We hypothesised that the data taken by the system pres-
ented here are suﬃciently accurate for pair-wise modelling up
to four populations, where the original populations have
already been characterised. To test this, mean analyses (n = 15)
of Jurkat cells were analysed before and after 16 h of treatment
with 10 µM doxorubicin (referred to as healthy control and
DOX-treated). Each analysis identified two populations: in the
first case, the sample was found to contain 90% healthy cells
and 10% which exhibited a significantly lower cytoplasmic
capacitance, suggesting cell damage perhaps due to cell hand-
ling (ESI Fig. 1A†). Two populations were also found in the
DOX-treated sample, one indicating apoptotic cells and the
other presenting much smaller particles (∼1 µm), suggested to
be apoptotic bodies, in a 54 : 46% ratio (ESI Fig. 1B†). The two
samples (HC and DOX) were then mixed in 25 : 75, 50 : 50 and
75 : 25 ratios and analysed with DEP using the average of five
repeats. Analysis was performed by using best-fit software to
estimate the ratios of the two established populations in which
the spectra derived for the HC and DOX cells should be mixed
in order to maximise the correlation coeﬃcient. Ratios were
estimated in 1% steps (and further 0.1% steps when necess-
ary), with the highest R value selected. The results can be seen
in Table 1; the system determined the ratios to an accuracy of
5% or better, with R-values ≥0.98 (and reaching up to 0.998). It
was noted that the variability in the DEP replicates was
increased for the treated sample indicating the heterogeneity
of sample may not be as consistent as the two populations
found in the healthy sample. This highlights the eﬀectiveness
of the system for the analysis of heterogeneous populations,
such as for cytotoxicity analysis.
IC50 determination of doxorubicin on Jurkat cells by MTT, DEP
and trypan blue
A common measurement of the eﬃcacy of cellular assays is
the determination of a response curve to a drug in order to
determine its inhibitory concentration that aﬀects 50% of
cells, or IC50. Jurkat cells are electrophysiologically trans-
formed by the use of anti-cancer drugs such as doxorubicin,
thus DEP may present a rapid, simple-to-use and low-cost
alternative to IC50 assay techniques such as MTT or trypan
blue. To determine the toxicity of doxorubicin on Jurkat cells,
the percentage of viable cells after incubation with each con-
centration is needed. We incubated Jurkat cells for 8–32 h with
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doxorubicin at concentrations between 0.1 to 1 μM. After 8 h
incubation with doxorubicin, in addition to the two popu-
lations similarly identified in ESI Fig. 1† for the healthy
control, a third population had lower membrane capacitance
and conductance and lower cytoplasmic conductivity and per-
mittivity. The second population is interpreted as being
aﬀected by the drug but not dead, as the trypan blue test did
not show that cells were necrotic.
After 16 h incubation with doxorubicin a fourth population,
with properties indicating a small radius, was found; closer
observation of the cells under the microscope confirmed the
presence of cell fragments approximately 1–2 µm in diameter.
At each time point, the established DEP properties of these
four populations were used to determine viability at each con-
centration (examples of this are shown in ESI Fig. 4† for 1 µM).
This was performed through iterating sub population percen-
tage, optimising R of the single shell fit to the spectra data.
DEP viability % was interpreted as the total percentage of sub
population 1 and 2. Again it was observed that the error associ-
ated with DEP replicates of the 32 h was higher than shorter
incubation times suggesting the heterogeneity of the sample
had increased. The eﬀect of doxorubicin on Jurkat cells was
also calculated by comparing the results at each concentration
against the healthy control using both trypan blue and MTT,
the results of which are shown in Table 3. For the lower con-
centration and shortened incubation times the MTT result was
negative, indicating that those cells proliferated more than the
healthy control. The numbers of trypan blue stained cells and
unstained cells were also measured for each experiment,
though this proved diﬃcult at times when most of the cells
were necrotic. There was a presence of ghost-like cells which
were diﬃcult to see under the microscope and appeared
brighter than the rest or had a pale-blue appearance. For the
experiments with the longer incubation times and higher con-
centrations, the cell concentration appeared to be lower and
the presence of very small debris was noticeable but diﬃcult
to quantify under the microscope.
The percentage of viable cells obtained using DEP, MTT
and trypan blue, for each concentration at a given time
point, was used to calculate the IC50 values with the Hill
Model by fitting to a rectangular hyperbola with iterative
least squares regression and error given is error of fit to data
points using Kaleidagraph (Synergy Software, Reading, PA
USA). Table 2 shows the IC50 values obtained with the
diﬀerent methods over time. Each DEP experiment results in
a dielectrophoretic spectrum from which populations with
diﬀerent properties can be obtained. The healthy population
is determined as a control and then after incubation with the
drug, the healthy population (which consists of two sub
populations) can be subtracted in order to obtain the pro-
perties of the remaining populations. In this study, the pro-
perties of the aﬀected cells and cell fragments are assumed
to be the same in all incubation time points and concen-
trations in order to obtain an estimate of their properties.
The DEP results highlighted the presence of three popu-
lations after 8 h, as can be seen from the bend in the polari-
sability at higher frequencies, indicating a population with a
lower membrane capacitance and cytoplasm conductivity.
After 16 h a fourth population, made up of cell fragments,
could be seen in the spectra. By 32 h, there was a noticeable
decrease in the healthy populations of each concentration.
The IC50 could be determined at this point and proved close
to the result obtained with MTT at both 16 h and 24 h; it was
also consistent with the value obtained by trypan blue at
32 h, though unlike DEP and MTT this method was unable
to produce a result at 16 h.
Table 1 Untreated Healthy Control (100% HC) and DOX-treated (100% DOX) Jurkat cell populations (n = 15), each determined to contain two sub-
populations. The properties of these sub populations are given at the bottom of the table. These two treatment groups were mixed in known ratios
(n = 7) as indicated on left-hand column by the % of HC. Keeping DEP properties constant for the HC and DOX sub populations, the single-shell
model was ﬁtted iteratively in steps of 0.1% of each population combination. For each iteration the Pearson correlation coeﬃcient (R) was deter-
mined. The mixture % in each column indicates the ratio of HC and DOX sub populations which provided the best over-all ﬁt. The totals of these
best ﬁt ratios can then be compared to the actual, known mixture (e.g. for the known 25% HC/75% DOX mixture, DEP best ﬁst occurred at 30%
HC/70% DOX)
Best fit % with constant parameters
Healthy
Control Total
Healthy Control
(sub-pop 1)
Healthy Control
(sub-pop 2)
DOX cells
(sub-pop 3)
DOX fragments
(sub-pop 4)
DOX
total
R
value
Known
mixture %
100%
HC
100% 90% 10% — — — 0.998
75% HC 75.0% 67.5% 7.5% 13.5% 11.5% 25.0% 0.9908
50% HC 55.0% 49.5% 5.5% 24.3% 20.7% 45.0% 0.9933
25% HC 30.0% 27.0% 3.0% 37.8% 32.2% 70.0% 0.9742
100%
DOX
— — — 54% 46% 100% 0.9943
Cytoplasmic conductivity (S m−1) 0.46 0.07 0.12 0.02
Cytoplasmic relative permittivity 60 60 80 70
Membrane conductance (S m−2) 25.0 12.5 12.5 1.3
Membrane capacitance (mF m−2) 9.96 7.75 6.64 7.75
Radius (µm) 6.5 6.0 5.5 1.0
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Cytotoxicity analysis of staurosporine on HeLa cells by MTT,
DEP, Annexin-V and trypan blue
Staurosporine is a widely-used agent for the induction of apop-
tosis. To benchmark DEP against common methods of viabi-
lity or apoptosis itself, HeLa cells were incubated with stauros-
porine and then DEP, flow cytometry, MTT and trypan blue
measured at regular time-points.
The mean (n = 14) DEP spectra of HeLa cells, together with
the modelled electrical parameters, are shown in ESI Fig. 2.†
Analysis of the control HeLa population indicated that 15% of
the population was small-radius debris, rising to 30% after
0.5 h incubation with staurosporine. After 0.5 h incubation
with staurosporine the healthy population (population 1) had
decreased by 18% and after 2 h by 41% compared to the
healthy control. The mean cell radius had increased from
7.7 µm to 8.1 µm, coinciding with a decrease in cytoplasmic
conductivity from 0.38 mS m−1 to 0.26 mS m−1 whilst the cyto-
plasmic permittivity remained the same. The membrane
capacitance decreased from 38.7 mF m−2 to 35.4 mF m−2
whilst the membrane conductance remained constant. After
2 hours, cell debris accounted for 50% of the population, but
the cell-sized population retained the cell properties as after
0.5 h, though the radius decreased to 7.26 µm (lower than the
healthy control, but within the standard deviations). After
0.5 h incubation with staurosporine the healthy population
(population 1) had decreased to 82% and after 2 h to 58%.
Flow cytometric analysis was performed for Propidium
Iodide (PI) and Annexin V-FITC; the latter adheres to phospha-
tidylserine exposed on the cell membrane during early apopto-
sis, whilst PI indicates loss of membrane integrity in late apop-
tosis. In all experiments 10 000 events were measured, of
which some fell outside the gating set by the control sample
(ESI Fig. 3†). The healthy control showed a small percentage of
early apoptotic cells, this could be because apoptosis can also
be induced by cell stress. It also contained a small percentage
of late apoptotic cells. After 0.5 h the healthy population
decreased by 4% and the early apoptotic population increased
by the same amount. The healthy population decreased as
incubation time was longer. The late apoptotic population
increased steadily as incubation time was longer.
The healthy control gated population was 77.4% of the
events registered. The 0.5 h, 2 h, 4 h, 6 h, and 12 h gated popu-
lations were 75.3%, 59.8%, 42.5%, 37%, and 24.6% of the
events registered, respectively. These results indicate that the
presence of cell debris increases steadily from 0.5 h of incu-
bation with 1 µM staurosporine. The viability determined by
flow cytometry is shown in Table 3.
The viability of HeLa cells after each incubation time point
was calculated by comparing their concentration against the
healthy control concentration. Table 2 shows the results
obtained with MTT. MTT was chosen in order to observe the
viability of the cell population without harvesting methods
Table 2 Comparison of IC50 of DOX on Jurkat cells using DEP, MTT and trypan blue. The growth inhibition was measured by MTT, whilst viability
was measured by trypan blue, (n = 5) and DEP (n = 7) of Jurkat cells incubated with doxorubicin at diﬀerent times. The viabilities For each treatment
time, the responses at each concentration were used to calculate the IC50 by ﬁtting data to a rectangular hyperbola with iterative least squares
regression; the error given is the error of ﬁt to data points using KaleidaGraph (Synergy Software, Reading, PA USA)a
0.1 µM 0.3 µM 0.5 µM 1 µM IC50
MTT: growth inhibition (%)
DOX incubation time 8 h −2.9 ± 0.013 −0.94 ± 0.014 2.7 ± 0.020 2.9± 0.026 0.37 ± 0.07
16 h 3.0 ± 0.006 −1.0 ± 0.036 34.2 ± 0.019 56.1 ± 0.006 1.21 ± 0.20
32 h 2.9 ± 0.019 50.5 ± 0.012 69.5 ± 0.003 79.5 ± 0.004 0.33 ± 0.04
Trypan blue: % viability
8 h 94 ± 3 96 ± 2 98 ± 1 99 ± 1 DNC
16 h 94 ± 3 97 ± 2 94 ± 1 82 ± 2 5.07 ± 0.75
32 h 94 ± 3 60 ± 5 29 ± 1 27 ± 2 0.36 ± 0.035
DEP: % viability (±1%)
8 h 90 94.5 83 85 0.14 ± 0.11
16 h 90 85 65 20 0.70 ± 0.11
32 h 90 40 35 0 0.25 ± 0.04
aDNC designates when Hill Model did not converge with given data.
Table 3 Comparison of HeLa cell viability after treatment with 1 µM staurosporine as measured by DEP (n = 14, ±SEM), trypan blue, ﬂow cytometry,
and MTT (n = 5, ±SEM)
Viability (%) measured by method
Trypan blue Flow cytometry MTT viability DEP
STS incubation time Healthy control 92 ± 1 91 ± 3 100 ± 0 85 ± 5
0.5 h 86 ± 3 87 ± 2 98 ± 1 70 ± 5
2 h 75 ± 5 73 ± 6 92 ± 1 50 ± 5
4 h 38 ± 1 27 ± 4 50 ± 1 0 ± 5
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aﬀecting the result. For the shorter incubation times the result
is negative, indicating that those cells proliferated more than
the healthy control. After 4 h (n = 5) MTT shows that half of
the population is still viable. For the healthy control the cell
viability was 98%. The viabilities for the incubation time
points were 98% at 0.5 h, 92% after 2 h, and 87% after 4 h.
The trypan blue experiments were carried out immediately
before the DEP experiments in order to determine cell viability
of the samples. The results, when compared with the flow cyto-
metry populations that are not stained with PI correlate well,
as seen in Table 3, indicating that DEP accords with flow cyto-
metry in terms of cells with intact membranes. Previous
results comparing DEP to other viability methods also showed
DEP to underestimate viability when compared to trypan blue
and flow cytometry, again suggesting DEP measures earlier
apoptotic events than these methods resulting in a lower DEP
viability measure. Confirmation of this could be found in this
same study, where Nexin (which detects an early apoptotic
feature of phosphatidylserine on the outer cell membrane) and
DEP demonstrated near identical viability counts.16 This is cor-
roborated with another DEP study that showed a strong
inverse relationship between PS externalisation and cyto-
plasmic conductivity.11
MTT overestimates the viability of the cells because during
the early stages of apoptosis the cell is still able to metabolise
the tetrazolium salt.5 MTT on adherent cells was carried out
whilst they were still attached to the microplate and, since no
detachment was needed, the cells were not harmed by the har-
vesting process. The MTT experiments showed that the cells
were viable from 0.5 h to 2 h. At 4 h, MTT estimated that half
of the population was viable. When incubated in suspension,
DEP detected a decrease in the healthy population after 0.5 h
incubation, and that population also had lower cytoplasmic
conductivity. The population had decreased to 80% (from 85%
to 70%) and cytoplasm conductivity from 0.38 to 0.26 S m−1.
Flow cytometry, for the 0.5 h sample, showed that the healthy
population had decreased to 95% (from 91 to 87%). When the
diﬀerent methods are compared (Table 3) it is clear that the
DEP result is comparable to both MTT and flow cytometry in
terms of viability assessment, whilst being faster and substan-
tially lower cost to implement.
DEP has previously been used to quantify apoptotic pro-
gression, detecting cells in early or late apoptosis from normal
cells.7–20 It can detect early events associated with the onset of
apoptosis in a manner which can be correlated with other
apoptotic events such as the activation of scramblases which
translocate membrane phospholipids between inner and outer
leaflets.11 However, whilst tools for the study of apoptosis
often focus on the analysis of the apoptotic process, a greater
part of the analysis is in the quantification of the number of
cells undergoing the phenomenon in order to determine the
eﬃcacy of drugs at diﬀerent concentrations. This has been
something that DEP has been previously unable to achieve,
because the majority of DEP analysis methods use cell tracking
in some form to measure the force on a population of cells.
Cells in late apoptosis tend to break into small (>2 µm)
particles known as “apoptotic bodies” that are too small to
track easily, making it diﬃcult to quantify how many cells
have entered this phase. The method described here uses a
diﬀerent approach, relying on the optical absorbance of cells
within a well structure. Typically, 1000 cells will be contained
within each well, with 20 wells being analysed. As cells disinte-
grate, they remain within the optical path and retain similar
absorbance characteristics, allowing them to remain as part of
the quantification process.
The multi-population model used here used four fixed
models for healthy cells plus those in apoptosis, tracking the
variation in population sizes by finding the best-fit proportions
of the four populations. The fits to the four curves were typi-
cally determined to have values of R2 > 0.99 and, when mixed
in fixed ratios, were accurate to within 5% of the actual popu-
lation ratios. When using these models to track actual cell
populations undergoing apoptosis there is good agreement
between DEP and the other methods. For Jurkat cells, results
with DEP typically produced a lower value by a factor of ∼2;
given that IC50 values typically deal with orders of magnitude,
this is functionally a very similar result. For HeLa cells where
the assay operated on much shorter timescales, DEP produced
a result much more rapidly than the other methods, princi-
pally because DEP measures cell stress rather than cell death,
by identifying ion eﬄux early in the apoptotic process, though
MTT did start to show similar results some 2 h later.
Taken together, these results suggest that DEP can be used
as an eﬀective tool for quantifying cell death. It produces
IC50 results comparable to standard assays such as MTT, flow
cytometry, and trypan blue. The technique does not require
any cell staining, is faster than the other methods, producing
functionally similar results with significantly lower complexity
and operating cost and has demonstrated sensitivity to physio-
logical changes in cells across early to late stage apoptosis.
Competing interests
KFH and MPH are directors of DEPtech Ltd, which produce
the 3DEP instrument used here.
Acknowledgements
Funding for this work was provided from the South East of
England Development Agency and Finance South East. A stu-
dentship to RMTS was provided by Labtech International.
References
1 M. M. Martinez, R. D. Reif and D. Pappas, Anal. Methods,
2010, 2, 996–1004.
2 V. A. Fadok, D. R. Voelker, P. A. Campbell, J. J. Cohen,
D. L. Bratton and P. M. Henson, J. Immunol., 1992, 148,
2207–2216.
Paper Analyst
6414 | Analyst, 2016, 141, 6408–6415 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
O
ct
ob
er
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
1/
11
/2
01
6 
15
:2
6:
52
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
3 G. Koopman, C. P. M. Reutelingsperger, G. A. M. Kuijten,
R. M. J. Keehnen, S. T. Pals and M. H. J. Vanoers, Blood,
1994, 84, 1415–1420.
4 M. van Engeland, F. C. Ramaekers, B. Schutte and
C. P. Reutelingsperger, Cytometry, 1996, 24, 131–139.
5 T. Mosmann, J. Immunol. Methods, 1983, 65, 55–63.
6 G. Ormerod, Flow Cytometry: A Practical Approach, OUP
Oxford, 2000.
7 S. Chin, M. P. Hughes, H. M. Coley and F. H. Labeed,
Int. J. Nanomed., 2006, 1, 333–337.
8 X. J. Wang, F. F. Becker and P. R. C. Gascoyne, Biochim.
Biophys. Acta, 2002, 1564, 412–420.
9 F. H. Labeed, H. M. Coley and M. P. Hughes, Biochim.
Biophys. Acta, Gen. Subj., 2006, 1760, 922–929.
10 L. Duncan, H. Shelmerdine, M. P. Hughes, H. M. Coley,
Y. Hübner and F. H. Labeed, Phys. Med. Biol., 2008, 53,
N1–N7.
11 H. J. Mulhall, A. Cardnell, K. F. Hoettges, F. H. Labeed and
M. P. Hughes, Integr. Biol., 2015, 7, 1396–1401.
12 R. Pethig and M. S. Talary, IET Nanobiotechnol., 2007, 1,
2–9.
13 S. J. Martin, C. P. Reutelingsperger, A. J. Mcgahon,
J. A. Rader, R. C. van Schi, D. M. Laface and D. T. Green,
J. Exp. Med., 1995, 341, 1545–1556.
14 C. D. Bortner and J. A. A. Cidowlski, Philos. Trans. R. Soc.,
2014, 369, 1638.
15 C.J Huang, A.L. Chen, L. Wang, M. Guo and J. Yu, Biomed.
Microdevices, 2007, 9, 335–343.
16 M. Nikolic-Jaric, T. Cabel, E. Salimi, A. Bhide, K. Braasch,
M. Butler, G. E. Bridges and D. J. Thomson,
Biomicrofluidics, 2013, 7, 024101.
17 D. Lee, B. Hwang, Y. Choi and B. Kim, Sens. Actuators, A,
2016, 242, 1–8.
18 D. Lee and B. Kim, Int. J. Precis. Eng. Man., 2015, 16, 609–
613.
19 K. Braasch, M. Nikolic-Jaric, T. Cabel, E. Salimi,
G. E. Bridges, D. J. Tmonson and M. Butler, Biotechnol.
Bioeng., 2013, 110, 2902–2914.
20 R. T. Kalyana Kumar, S. Liu, J. D. Minna and S. Prasad,
Biochim. Biophys. Acta, 2016, 1860, 1877–1883.
21 C. H. Fry, S. C. Salvage, A. Manazza, E. Dupont,
F. H. Labeed, M. P. Hughes and R. I. Jabr, Biophys. J., 2012,
103, 2287–2294.
22 S. Mahabadi, F. H. Labeed and M. P. Hughes,
Electrophoresis, 2015, 36, 1493–1498.
23 Y. Hübner, K. F. Hoettges, G. E. N. Kass, S. L. Ogin and
M. P. Hughes, IEEE Proc. Bionanotechnol., 2005, 4, 21–25.
24 K. F. Hoettges, Y. Hübner, L. M. Broche, S. L. Ogin,
G. E. N. Kass and M. P. Hughes, Anal. Chem., 2008, 80,
2063–2068.
25 L. M. Broche, K. F. Hoettges, S. L. Ogin, G. E. N. Kass and
M. P. Hughes, Electrophoresis, 2011, 32, 2393–2399.
26 A. Irimajiri, T. Hanai and A. Inouye, J. Theor. Biol., 1979,
78, 251–269.
27 U. Lei, P. H. Sun and R. Pethig, Biomicrofluidics, 2011, 5,
044109.
28 L. M. Broche, F. H. Labeed and M. P. Hughes, Phys. Med.
Biol., 2005, 50, 2267–2274.
29 S. Goutelle, M. Maurin, F. Rougier, X. Barbaut,
L. Bourguignon, M. Ducher and P. Maire, Fundam. Clin.
Pharmacol., 2008, 22, 633–648.
30 A. V. Hill, J. Physiol., 1910, 40(suppl.), iv–vii.
Analyst Paper
This journal is © The Royal Society of Chemistry 2016 Analyst, 2016, 141, 6408–6415 | 6415
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
O
ct
ob
er
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
1/
11
/2
01
6 
15
:2
6:
52
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
